Clinical utility of type 1 growth factor receptor expression in colon cancer

American Journal of Surgery

Volumn 195, Issue 5, 2008, Pages 604-610

  Leung, Sher Ping ^a,b   Griffith, Obi L ^b,c,d   Masoudi, Hamid ^b   Gown, Allen ^b,e   Jones, Steven ^b,c,d   Phang, Terry ^a,b   Wiseman, Sam M ^a,b,f  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d CANADA'S MICHAEL SMITH GENOME SCIENCES CENTRE   (Canada)

^e PHENOPATH LABORATORIES   (United States)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Colon cancer; HER 1; HER 2; HER 3; HER 4; Tissue microarray; Type 1 growth factor receptor family

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR TYPE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLINICAL FEATURE; COLON CARCINOMA; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 42049116067     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2007.12.032     Document Type: Article

References (35)

1. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 13 (2000) 3159-3167
2. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 3 (1995) 183-232
3. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 4 (2001) S3-S8
4. Prigent S.A., and Lemoine N.R. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Prog Growth Factor Res 4 (1992) 1-24
5. Lee J.C., Wang S.T., Chow N.H., et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 8 (2002) 1065-1071
6. Grandis J.R., and Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 1 (2004) 37-46
7. Parker R.L., Huntsman D.G., Lesack D.W., et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 5 (2002) 723-728
8. Goldstein N.S., and Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American joint committee on cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 5 (2001) 1331-1346
9. McKay J.A., Murray L.J., Curran S., et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 17 (2002) 2258-2264
10. Doger F.K., Meteoglu I., Tuncyurek P., et al. Does the EGFR and VEGF expression predict the prognosis in colon cancer?. Eur Surg Res 6 (2006) 540-544
11. Galizia G., Lieto E., Ferraraccio F., et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 6 (2006) 823-835
12. Khorana A.A., Ryan C.K., Cox C., et al. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer 4 (2003) 960-968
13. Resnick M.B., Routhier J., Konkin T., et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 9 (2004) 3069-3075
14. Essapen S., Thomas H., Green M., et al. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 2 (2004) 241-248
15. Osako T., Miyahara M., Uchino S., et al. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 6 (1998) 548-555
16. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 4 (2004) 337-345
17. Rossi H.A., Liu Q., Banner B., et al. The prognostic value of invariant chain (ii) and her-2/neu expression in curatively resected colorectal cancer. Cancer J 3 (2002) 268-275
18. Ishida H., Sadahiro S., Suzuki T., et al. c-erbB-2 protein expression and clinicopathologic features in colorectal cancer. Oncol Rep 6 (2000) 1229-1233
19. Kountourakis P., Pavlakis K., Psyrri A., et al. Clinicopathologic significance of EGFR and her-2/neu in colorectal adenocarcinomas. Cancer J 3 (2006) 229-236
20. Half E., Broaddus R., Danenberg K.D., et al. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 4 (2004) 540-548
21. Ooi A., Takehana T., Li X., et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 8 (2004) 895-904
22. Kapitanović S., Radosevic S., Kapitanovic M., et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 4 (1997) 1103-1113
23. Ramanathan R.K., Hwang J.J., Zamboni W.C., et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 6 (2004) 858-865
24. Maurer C.A., Friess H., Kretschmann B., et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 8 (1998) 771-777
25. Knosel T., Yu Y., Stein U., et al. Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. Clin Exp Metastasis 5 (2002) 401-407
26. Nakae S., Shimada E., and Urakawa T. Study of c-erbB-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. J Surg Oncol 4 (1993) 246-251
27. Kapitanovic S., Radosevic S., Slade N., et al. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 4 (2000) 205-211
28. Kountourakis P., Pavlakis K., Psyrri A., et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6 (2006) 46-54
29. Porebska I., Harlozinska A., and Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2 (2000) 105-115
30. Lenferink A., Pinkas-Kramarski R., van de Poll M.L.M., et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 12 (1998) 3385-3397
31. Vadlamudi R., Mandal M., Adam L., et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 2 (1999) 305-314
32. Buck E., Eyzaguirre A., Haley J.D., et al. Inactivation of akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 8 (2006) 2051-2059
33. Scartozzi M., Bearzi I., Berardi R., et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22 (2004) 4772-4777
34. VanCutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 9 (2006) 1010-1017
35. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 9 (2005) 1803-1810